CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2017--
Therapeutics, Inc. (NASDAQ:MRSN), today announced that Anna
Protopapas, President and Chief Executive Officer, will present a
company overview at the Wedbush PacGrow Healthcare Conference in New
York City on Wednesday, August 16, 2017, from 10:20-10:50am EDT.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using
its differentiated and proprietary ADC platforms to develop highly
targeted drugs with increased tolerability and expanded opportunities to
deliver meaningful clinical benefit to patients. Mersana’s lead product
candidate, XMT-1522, is in Phase I clinical trials in patients with
advanced tumors expressing HER2, including breast cancer,
non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The
Company expects that its second product candidate, XMT-1536, will enter
clinical trials in early 2018. In addition, multiple partners are using
Mersana’s leading platform to advance their ADC pipelines.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170809005756/en/
Source: Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc.
Stern Investor Relations, Inc.